-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
TextPharmaceutical Guanlan
Today (December 23), Lion TCR Pte Ltd (Lion TCR Pte Ltd, hereinafter referred to as "Lion Bio") announced that its potential "first-in-class" therapy LioCyx-M004 has been granted Fast Track by the US FDA Eligibility for the treatment of hepatitis B-related hepatocellular carcinoma
Lyon Bio is a clinical-stage biotechnology company
LioCyx-M004 is the product with the fastest research progress in Lyon's product pipeline
In early Phase 1 clinical studies, LioCyx-M004 has demonstrated a good safety profile and significantly improved patient survival
Dr.
Dr.
According to the press release, there are 420,000 new patients with hepatitis B-related hepatocellular carcinoma each year.
References:
[1] Lion Bio received FDA Fast Track Designation: Application of HBV-specific TCR-T in the treatment of hepatocellular carcinoma.